Theranos' Future Hangs On A ThreadMark Melin
Controversial medical laboratory services company Theranos could be in the throws a crisis. Late Thursday regulators revealed the company’s high-profile blood tests failed quality control tests almost 30% of the time. The report, which was leaked to The Wall Street Journal, paints a troubling picture of a company tagged with a $9 billion valuation based on an easy and inexpensive finger-prick blood test that was promoted . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.